15 March 2023 - argenx is committed to collaborating with local authorities to facilitate broad and rapid access to Vyvgart for eligible patients.

argenx today announced that the UK MHRA has granted marketing authorization for Vyvgart (efgartigimod alfa-fcab) as an add-on to standard therapy for the treatment of adult patients with generalised myasthenia gravis who are anti-acetylcholine receptor antibody positive.

Read argenyx press release